Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals Inc (NQ: AVIR )

4.600 +0.030 (+0.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 292,559
Open 4.550
Bid (Size) 4.500 (1)
Ask (Size) 4.660 (3)
Prev. Close 4.570
Today's Range 4.530 - 4.640
52wk Range 4.175 - 9.790
Shares Outstanding 83,287,639
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
-4.37%
-4.37%
1 Month
+5.75%
+5.75%
3 Month
-22.03%
-22.03%
6 Month
-43.90%
-43.90%
1 Year
-28.46%
-28.46%

More News

Read More
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
Via Benzinga
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
Via Benzinga
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Atea Pharmaceuticals Earnings Preview
Via Benzinga
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Recap: Atea Pharmaceuticals Q2 Earnings
Via Benzinga
Short Volatility Alert: Atea Pharmaceuticals
Via Benzinga
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
From Atea Pharmaceuticals, Inc.
Via Globe NewsWire
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Via Investor's Business Daily
Stocks Selling For Less Than Cash Per Share
Via Talk Markets
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Atea Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Earnings Preview For Atea Pharmaceuticals
Via Benzinga
How To Attend Atea Pharmaceuticals Q1 2022 Earnings Conference Call
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
NASDAQ:AVIR Investor Notice: Investigation over Potential Wrongdoing at Atea Pharmaceuticals, Inc.
Via SBWire
30 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
27 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.